title: [Pharmacodynamic approach to the optimal use of calcium antagonists in patients with cerebrovascular disorders].
abstract: Three hours after administration of a single 20 mg dose of nifedipine the platelet, leucocyte and red blood cells aggregation was inhibited with the red blood cells and leucocytes deformability increased. This effect proved sensitive to the plasma nifedipine concentration disappearing with its concentrations below 25 ng/ml. The nifedipine sensitivity of the blood cells was the second factor influencing its effect. This was closely related to prostacyclin. The blood cells sensitivity to the latter, and its plasma concentration and decay rates were major determinants of the nifedipine capability of inhibiting the leucocyte, red blood cells and especially platelet inhibition.
authors.forename: S E
authors.initials: SE
authors.lastname: Akopov
authors.forename: G S
authors.initials: GS
authors.lastname: Grigorian
authors.forename: Iu S
authors.initials: IuS
authors.lastname: Tunian
authors.forename: E S
authors.initials: ES
authors.lastname: Gabrielian
mesh_terms: D000368:Aged; D002561:Cerebrovascular Disorders / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004903:Erythrocyte Aggregation / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects* / Q000473:pathology; D009543:Nifedipine / Q000008:administration & dosage*; D010974:Platelet Aggregation / Q000187:drug effects* / Q000502:physiology; D010975:Platelet Aggregation Inhibitors; D013997:Time Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D009543:Nifedipine
vernacular_title: Farmakodinamicheskie podkhody k optimizatsii primeneniia antagonistov kal'tsiia u bol'nykh s tserebrovaskuliarnymi zabolevaniiami.